When small Phase II trials aren't powered to show efficacy, questions always remain as to whether to go into Phase III studies. Icos Corp. believes that the Phase II safety profile of its LeukArrest monoclonal antibody to treat acute ischemic stroke justified the start of an 800-patient Phase III trial last week. The company said an interim analysis of the Phase